Fangzhou（5UD）株式概要方舟社は中国でオンライン慢性疾患管理サービスを提供している。 詳細5UD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績3/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より82.2%で取引されている 収益は年間25.08%増加すると予測されています 今年は黒字化を達成 リスク分析German市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る5UD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.09857.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-855m11b2016201920222025202620282031Revenue CN¥10.8bEarnings CN¥36.2mAdvancedSet Fair ValueView all narrativesFangzhou Inc. 競合他社Hawesko HoldingSymbol: XTRA:HAWMarket cap: €178.3mWASGAU Produktions & HandelsSymbol: DB:MSHMarket cap: €57.4mCareRxSymbol: TSX:CRRXMarket cap: CA$222.7mYAKUODO HOLDINGSSymbol: TSE:7679Market cap: JP¥33.4b価格と性能株価の高値、安値、推移の概要Fangzhou過去の株価現在の株価HK$0.09852週高値HK$0.5452週安値HK$0.095ベータ01ヶ月の変化-22.00%3ヶ月変化-61.31%1年変化-76.10%3年間の変化n/a5年間の変化n/aIPOからの変化-86.50%最新ニュースお知らせ • May 22Fangzhou Inc., Annual General Meeting, Jun 16, 2026Fangzhou Inc., Annual General Meeting, Jun 16, 2026, at 09:30 China Standard Time.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Xiaolu Zhu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14Fangzhou Inc. Showcases Ai+H2h Chronic Disease Service InnovationsFangzhou Inc. participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub-forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital-to-Home) ecosystem supports a full-cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post-clinic follow-up, improve access to services, and extend care to more patients. Chronic disease management requires long-term engagement. Fangzhou centers its approach on structured follow-ups, evolving from one-off consultations to continuous care over the full course of a patient’s condition. AI-powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long-term members also gain access to tailored health plans, dynamic monitoring, early-warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support. In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long-term health partner, using technology to deliver accessible, high-quality chronic disease management and to set a benchmark for sustainable innovation in healthcare.お知らせ • Mar 27+ 1 more updateFangzhou Inc. Announces Appointment of Wang Haijiao as Chief Executive Officer, Effective March 26, 2026Fangzhou Inc. announced the appointment of Mr. WANG Haijiao as Chief Executive Officer, effective March 26, 2026. Mr. Wang brings nearly 20 years of extensive experience in entrepreneurship, management, and investment within the healthcare industry. He holds deep expertise in digital health, precision medicine, and in vitro diagnostics (IVD). Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014. He previously served as an investment director at Dragon Rise Capital and currently serves as a director of Guangzhou LBP Medicine Science & Technology Co. Ltd. Mr. Wang holds a master’s degree in microbiology and an MBA from Fudan University, as well as an EMBA from the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University.お知らせ • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026お知らせ • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • May 22Fangzhou Inc., Annual General Meeting, Jun 16, 2026Fangzhou Inc., Annual General Meeting, Jun 16, 2026, at 09:30 China Standard Time.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Xiaolu Zhu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14Fangzhou Inc. Showcases Ai+H2h Chronic Disease Service InnovationsFangzhou Inc. participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub-forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital-to-Home) ecosystem supports a full-cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post-clinic follow-up, improve access to services, and extend care to more patients. Chronic disease management requires long-term engagement. Fangzhou centers its approach on structured follow-ups, evolving from one-off consultations to continuous care over the full course of a patient’s condition. AI-powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long-term members also gain access to tailored health plans, dynamic monitoring, early-warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support. In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long-term health partner, using technology to deliver accessible, high-quality chronic disease management and to set a benchmark for sustainable innovation in healthcare.お知らせ • Mar 27+ 1 more updateFangzhou Inc. Announces Appointment of Wang Haijiao as Chief Executive Officer, Effective March 26, 2026Fangzhou Inc. announced the appointment of Mr. WANG Haijiao as Chief Executive Officer, effective March 26, 2026. Mr. Wang brings nearly 20 years of extensive experience in entrepreneurship, management, and investment within the healthcare industry. He holds deep expertise in digital health, precision medicine, and in vitro diagnostics (IVD). Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014. He previously served as an investment director at Dragon Rise Capital and currently serves as a director of Guangzhou LBP Medicine Science & Technology Co. Ltd. Mr. Wang holds a master’s degree in microbiology and an MBA from Fudan University, as well as an EMBA from the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University.お知らせ • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026お知らせ • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listingお知らせ • Jan 27Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listingお知らせ • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.お知らせ • Nov 27Fangzhou Inc. and Tencent Healthcare Launch Full-Stack AI Solution for Chronic-Disease ManagementFangzhou Inc. and Tencent Healthcare jointly launched a comprehensive "AI+Chronic Disease Management" solution, marking a major step in the wider deployment of artificial intelligence across China's healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery. The solution is built on Fangzhou's AI+H2H (H Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management. This launch follows Fangzhou's recent AI growth momentum. The October introduction of the Company's "medical report interpretation" feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities. Safety and compliance remain central to Fangzhou's approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks. Fangzhou has built its model on Tencent Healthcare's TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare's vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic evaluation and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare's AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI. The partnership aligns closely with the National Health Commission's recently issued guidelines on developing safe, standardized "AI + healthcare" applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the "Healthy China 2030" initiative.お知らせ • Oct 22Fangzhou Inc. Announces Leveraging Its Proprietary “Xingshi” Large Language ModelFangzhou Inc. announced leveraging its proprietary “XingShi” Large Language Model (“XS LLM”), the company's system integrates AI-enabled tools such as its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to deliver a closed-loop weight management solution. Users can upload their BMI data or health reports to receive tailored recommendations, while patients requiring medication can access 24/7 AI-assisted guidance and follow-up support from licensed medical professionals. Earlier this year, Fangzhou announced strategic partnerships with Novo Nordisk and Innovent Biologics to build AI-powered weight management solutions, representing a significant advance in digital healthcare collaboration. At the symposium, Fangzhou was named as a founding core enterprise of the national “Healthy China: AI + Weight Management Pioneer” initiative, a collaborative effort focused on setting industry standards, fostering innovation, and educating the public on evidence-based weight management. Looking ahead, Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration. By building a smart, standardized, and collaborative framework, the Company aims to transform China’s weight management landscape and contribute to long-term national health priorities.お知らせ • Sep 15Fangzhou Unveils "XingShi" Large Language Model to Advance AI-Driven Chronic Disease ManagementFangzhou Inc. announced the release of its proprietary "XingShi" Large Language Model ("XS LLM"), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians' available time. XS LLM integrates multimodal capabilities -- image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning -- while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: "AI Knowledge Agent", "AI Guidance Agent", "AI Pre-Consult Agent", "AI Doctor Assistant", and "AI-Electronic Medical Record (EMR) Agent". Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management. Built as the "core digital brain" of Fangzhou's platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference. This launch reflects Fangzhou's steady AI build-out: from the introduction of its H2H (Hospital-to-Home) digital ecosystem, to the deployment of AI-powered customer service and knowledge base systems, and now to an enterprise-grade medical LLM. With China's "AI+" policy framework accelerating industrial adoption, Fangzhou indicated that XS LLM will anchor future R&D in chronic disease management applications, reinforcing its mission of delivering scalable, precision healthcare.お知らせ • Aug 15Fangzhou Inc. to Report First Half, 2025 Results on Aug 27, 2025Fangzhou Inc. announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 20Fangzhou Inc. Appoints KANG Wei as Member of Nomination Committee, Effective from June 18, 2025The board of directors of Fangzhou Inc. announced that, Ms. KANG Wei, an independent non-executive Director, has been appointed as a member of the nomination committee of the Company, effective from June 18, 2025. Following this appointment, the Nomination Committee now comprises four members, namely Mr. XIE Fangmin (chairman), Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu.お知らせ • May 28Fangzhou Inc., Annual General Meeting, Jun 19, 2025Fangzhou Inc., Annual General Meeting, Jun 19, 2025, at 09:15 China Standard Time.お知らせ • Apr 14Fangzhou Presents Ai-Driven Healthcare Ecosystem At Guangzhou Biotech Innovation SalonFangzhou Inc. participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Mitigate AI hallucinations: The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou's "AI Agent Matrix," featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs. Blueprint for Vertical AI Leadership: Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare. AI-Powered Growth Strategy: Fangzhou's growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company's technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users.お知らせ • Mar 12Fangzhou Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025Fangzhou Inc. announced that they will report fiscal year 2024 results on Mar 21, 2025お知らせ • Feb 18Fangzhou Inc. Integrates DeepSeek Open-Source Ai Model to Enhance Internet HealthcareFangzhou Inc. announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model on February 8th. This upgrade is expected to yield improvements in the company's service capabilities and operational efficiency, enabling more precise and personalized healthcare solutions for patients and healthcare providers, contributing to the overall advancement of the Internet healthcare sector. The local deployment of DeepSeek-R1's advanced analytical and reasoning capabilities allows Fangzhou to deliver data-driven decision support and advanced functionality, while maintaining full control over privacy and data security. By leveraging DeepSeek's technical strengths, the platform can more effectively address the needs of a diverse user base of patients and healthcare providers. For Patients: The platform enhances health management by providing analysis of medical reports, test results, and other health data. Leveraging these insights, healthcare providers are able to offer medication guidance, and post-diagnosis care plans. For Healthcare Providers: Fangzhou's DeepSeek-R1 powered "AI Assistant" can streamline prescription reviews and patient management, allowing doctors to focus on more critical medical tasks. The model's data-driven logic also incorporates science-based decision support, aiding in diagnosis and optimized treatment plans.お知らせ • Dec 02Fangzhou Inc. Launches AI Agent SolutionFangzhou Inc. unveiled its healthcare-focused "AI Agent Solution", a suite of tools designed to facilitate access to healthcare information and analysis for both consumers and healthcare professionals. Consumers can utilize Fangzhou's mini program to easily find health and diagnosis information, along with easy-to-understand "personalized interpretation" of over fifty types of medical reports. For healthcare providers, Fangzhou's "AI Academic Interaction Assistant" enhances the efficiency of scientific content research, with support for voice input, and Chinese/English bilingual search output, and automated literature summaries, significantly reducing search time by up to 80%. This commitment to technological innovation not only creates new pathways for health management but also supports Fangzhou's mission of empowering users and healthcare professionals alike with cutting-edge solutions.株主還元5UDDE Consumer RetailingDE 市場7D-10.6%2.6%2.4%1Y-76.1%-31.5%1.2%株主還元を見る業界別リターン: 5UD過去 1 年間で-31.5 % の収益を上げたGerman Consumer Retailing業界を下回りました。リターン対市場: 5UDは、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 5UD's price volatile compared to industry and market?5UD volatility5UD Average Weekly Movement12.8%Consumer Retailing Industry Average Movement8.1%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: 5UDの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 5UDの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015494Haijiao WangJianke.com株式会社方舟は、中国でオンライン慢性疾患管理サービスを提供している。同社は、オンライン慢性疾患管理プラットフォームを通じて、高血圧、心血管、呼吸器系慢性疾患などの慢性疾患患者のニーズに対応するサービスを提供している。モバイルアプリケーションを通じたオンライン医療相談サービス、電子処方箋、処方箋補充サービスを含むH2Hサービス、オンライン小売薬局サービスプラットフォームを通じたヘルスケア製品、カスタマイズされたコンテンツとマーケティングソリューションを提供し、病院の運営も行っている。同社は2015年に設立され、中国の広州を拠点としている。もっと見るFangzhou Inc. 基礎のまとめFangzhou の収益と売上を時価総額と比較するとどうか。5UD 基礎統計学時価総額€138.63m収益（TTM）€1.50m売上高(TTM)€447.15m92.4xPER（株価収益率0.3xP/Sレシオ5UD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計5UD 損益計算書（TTM）収益CN¥3.53b売上原価CN¥2.97b売上総利益CN¥559.44mその他の費用CN¥547.61m収益CN¥11.83m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.0085グロス・マージン15.87%純利益率0.34%有利子負債／自己資本比率2.6%5UD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:02終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fangzhou Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Ruili BianCitigroup IncChujie SunGelonghui Research
お知らせ • May 22Fangzhou Inc., Annual General Meeting, Jun 16, 2026Fangzhou Inc., Annual General Meeting, Jun 16, 2026, at 09:30 China Standard Time.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Xiaolu Zhu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14Fangzhou Inc. Showcases Ai+H2h Chronic Disease Service InnovationsFangzhou Inc. participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub-forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital-to-Home) ecosystem supports a full-cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post-clinic follow-up, improve access to services, and extend care to more patients. Chronic disease management requires long-term engagement. Fangzhou centers its approach on structured follow-ups, evolving from one-off consultations to continuous care over the full course of a patient’s condition. AI-powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long-term members also gain access to tailored health plans, dynamic monitoring, early-warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support. In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long-term health partner, using technology to deliver accessible, high-quality chronic disease management and to set a benchmark for sustainable innovation in healthcare.
お知らせ • Mar 27+ 1 more updateFangzhou Inc. Announces Appointment of Wang Haijiao as Chief Executive Officer, Effective March 26, 2026Fangzhou Inc. announced the appointment of Mr. WANG Haijiao as Chief Executive Officer, effective March 26, 2026. Mr. Wang brings nearly 20 years of extensive experience in entrepreneurship, management, and investment within the healthcare industry. He holds deep expertise in digital health, precision medicine, and in vitro diagnostics (IVD). Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014. He previously served as an investment director at Dragon Rise Capital and currently serves as a director of Guangzhou LBP Medicine Science & Technology Co. Ltd. Mr. Wang holds a master’s degree in microbiology and an MBA from Fudan University, as well as an EMBA from the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University.
お知らせ • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026
お知らせ • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing
お知らせ • May 22Fangzhou Inc., Annual General Meeting, Jun 16, 2026Fangzhou Inc., Annual General Meeting, Jun 16, 2026, at 09:30 China Standard Time.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Xiaolu Zhu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14Fangzhou Inc. Showcases Ai+H2h Chronic Disease Service InnovationsFangzhou Inc. participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub-forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital-to-Home) ecosystem supports a full-cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post-clinic follow-up, improve access to services, and extend care to more patients. Chronic disease management requires long-term engagement. Fangzhou centers its approach on structured follow-ups, evolving from one-off consultations to continuous care over the full course of a patient’s condition. AI-powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long-term members also gain access to tailored health plans, dynamic monitoring, early-warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support. In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long-term health partner, using technology to deliver accessible, high-quality chronic disease management and to set a benchmark for sustainable innovation in healthcare.
お知らせ • Mar 27+ 1 more updateFangzhou Inc. Announces Appointment of Wang Haijiao as Chief Executive Officer, Effective March 26, 2026Fangzhou Inc. announced the appointment of Mr. WANG Haijiao as Chief Executive Officer, effective March 26, 2026. Mr. Wang brings nearly 20 years of extensive experience in entrepreneurship, management, and investment within the healthcare industry. He holds deep expertise in digital health, precision medicine, and in vitro diagnostics (IVD). Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014. He previously served as an investment director at Dragon Rise Capital and currently serves as a director of Guangzhou LBP Medicine Science & Technology Co. Ltd. Mr. Wang holds a master’s degree in microbiology and an MBA from Fudan University, as well as an EMBA from the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University.
お知らせ • Mar 09Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026
お知らせ • Feb 02Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 27Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million.Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 45,181,000 Price\Range: HKD 3.32 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 26Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions.
お知らせ • Nov 27Fangzhou Inc. and Tencent Healthcare Launch Full-Stack AI Solution for Chronic-Disease ManagementFangzhou Inc. and Tencent Healthcare jointly launched a comprehensive "AI+Chronic Disease Management" solution, marking a major step in the wider deployment of artificial intelligence across China's healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery. The solution is built on Fangzhou's AI+H2H (H Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management. This launch follows Fangzhou's recent AI growth momentum. The October introduction of the Company's "medical report interpretation" feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities. Safety and compliance remain central to Fangzhou's approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks. Fangzhou has built its model on Tencent Healthcare's TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare's vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic evaluation and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare's AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI. The partnership aligns closely with the National Health Commission's recently issued guidelines on developing safe, standardized "AI + healthcare" applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the "Healthy China 2030" initiative.
お知らせ • Oct 22Fangzhou Inc. Announces Leveraging Its Proprietary “Xingshi” Large Language ModelFangzhou Inc. announced leveraging its proprietary “XingShi” Large Language Model (“XS LLM”), the company's system integrates AI-enabled tools such as its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to deliver a closed-loop weight management solution. Users can upload their BMI data or health reports to receive tailored recommendations, while patients requiring medication can access 24/7 AI-assisted guidance and follow-up support from licensed medical professionals. Earlier this year, Fangzhou announced strategic partnerships with Novo Nordisk and Innovent Biologics to build AI-powered weight management solutions, representing a significant advance in digital healthcare collaboration. At the symposium, Fangzhou was named as a founding core enterprise of the national “Healthy China: AI + Weight Management Pioneer” initiative, a collaborative effort focused on setting industry standards, fostering innovation, and educating the public on evidence-based weight management. Looking ahead, Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration. By building a smart, standardized, and collaborative framework, the Company aims to transform China’s weight management landscape and contribute to long-term national health priorities.
お知らせ • Sep 15Fangzhou Unveils "XingShi" Large Language Model to Advance AI-Driven Chronic Disease ManagementFangzhou Inc. announced the release of its proprietary "XingShi" Large Language Model ("XS LLM"), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians' available time. XS LLM integrates multimodal capabilities -- image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning -- while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: "AI Knowledge Agent", "AI Guidance Agent", "AI Pre-Consult Agent", "AI Doctor Assistant", and "AI-Electronic Medical Record (EMR) Agent". Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management. Built as the "core digital brain" of Fangzhou's platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference. This launch reflects Fangzhou's steady AI build-out: from the introduction of its H2H (Hospital-to-Home) digital ecosystem, to the deployment of AI-powered customer service and knowledge base systems, and now to an enterprise-grade medical LLM. With China's "AI+" policy framework accelerating industrial adoption, Fangzhou indicated that XS LLM will anchor future R&D in chronic disease management applications, reinforcing its mission of delivering scalable, precision healthcare.
お知らせ • Aug 15Fangzhou Inc. to Report First Half, 2025 Results on Aug 27, 2025Fangzhou Inc. announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 20Fangzhou Inc. Appoints KANG Wei as Member of Nomination Committee, Effective from June 18, 2025The board of directors of Fangzhou Inc. announced that, Ms. KANG Wei, an independent non-executive Director, has been appointed as a member of the nomination committee of the Company, effective from June 18, 2025. Following this appointment, the Nomination Committee now comprises four members, namely Mr. XIE Fangmin (chairman), Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu.
お知らせ • May 28Fangzhou Inc., Annual General Meeting, Jun 19, 2025Fangzhou Inc., Annual General Meeting, Jun 19, 2025, at 09:15 China Standard Time.
お知らせ • Apr 14Fangzhou Presents Ai-Driven Healthcare Ecosystem At Guangzhou Biotech Innovation SalonFangzhou Inc. participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Mitigate AI hallucinations: The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou's "AI Agent Matrix," featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs. Blueprint for Vertical AI Leadership: Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare. AI-Powered Growth Strategy: Fangzhou's growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company's technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users.
お知らせ • Mar 12Fangzhou Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025Fangzhou Inc. announced that they will report fiscal year 2024 results on Mar 21, 2025
お知らせ • Feb 18Fangzhou Inc. Integrates DeepSeek Open-Source Ai Model to Enhance Internet HealthcareFangzhou Inc. announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model on February 8th. This upgrade is expected to yield improvements in the company's service capabilities and operational efficiency, enabling more precise and personalized healthcare solutions for patients and healthcare providers, contributing to the overall advancement of the Internet healthcare sector. The local deployment of DeepSeek-R1's advanced analytical and reasoning capabilities allows Fangzhou to deliver data-driven decision support and advanced functionality, while maintaining full control over privacy and data security. By leveraging DeepSeek's technical strengths, the platform can more effectively address the needs of a diverse user base of patients and healthcare providers. For Patients: The platform enhances health management by providing analysis of medical reports, test results, and other health data. Leveraging these insights, healthcare providers are able to offer medication guidance, and post-diagnosis care plans. For Healthcare Providers: Fangzhou's DeepSeek-R1 powered "AI Assistant" can streamline prescription reviews and patient management, allowing doctors to focus on more critical medical tasks. The model's data-driven logic also incorporates science-based decision support, aiding in diagnosis and optimized treatment plans.
お知らせ • Dec 02Fangzhou Inc. Launches AI Agent SolutionFangzhou Inc. unveiled its healthcare-focused "AI Agent Solution", a suite of tools designed to facilitate access to healthcare information and analysis for both consumers and healthcare professionals. Consumers can utilize Fangzhou's mini program to easily find health and diagnosis information, along with easy-to-understand "personalized interpretation" of over fifty types of medical reports. For healthcare providers, Fangzhou's "AI Academic Interaction Assistant" enhances the efficiency of scientific content research, with support for voice input, and Chinese/English bilingual search output, and automated literature summaries, significantly reducing search time by up to 80%. This commitment to technological innovation not only creates new pathways for health management but also supports Fangzhou's mission of empowering users and healthcare professionals alike with cutting-edge solutions.
